QQ客服 官方微博 反馈留言

	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
	Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng
	2018
卷号	6期号:9页码:681-690
ISSN号	2213-2600
DOI	10.1016/S2213-2600(18)30264-9
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6356249
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wang, Zhijie,Cheng, Ying,An, Tongtong,et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial[J],2018,6(9):681-690.
APA	Wang, Zhijie.,Cheng, Ying.,An, Tongtong.,Gao, Hongjun.,Wang, Kai.,...&Wang, Jie.(2018).Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.,6(9),681-690.
MLA	Wang, Zhijie,et al."Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial".6.9(2018):681-690.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。